Hyaluronic acid products are frequently used in treatment of osteoarthritis and joint pain. It is a glycosaminoglycan present naturally in human body and act as a lubricant and shock absorber. Hyaluronic acid products are available in the form of injections, oral supplements and topical gels or creams. They help in improving joint mobility, reduces inflammation and alleviates pain associated with osteoarthritis.
The global Hyaluronic Acid Products Market is estimated to be valued at US$ 3,343.5 Mn in 2023 and is expected to exhibit a CAGR of 7.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
Rising geriatric population worldwide prone to joint disorders like osteoarthritis has opened tremendous growth opportunity for hyaluronic acid products market. As per estimates, around 10-15% of adult population aged over 60 years’ experience painful osteoarthritis. This percentage is expected to increase further in coming years due to aging population. Hyaluronic acid being a safe and effective alternative treatment option for alleviating joint pain associated with osteoarthritis makes it highly suitable for geriatric patients. Growing elderly base and their preference for non-invasive treatment modalities is anticipated to boost demand for hyaluronic acid products over forecast period, thereby propelling market growth.
Porter's Analysis
Threat of new entrants: Low barrier to entry with increasing research and development. Minimal capital required for new companies. However, the hyaluronic acid products market is dominated by key established players making it difficult for new players.
Bargaining power of buyers: High due to presence of many substitute products and availability of generics at lower prices. Buyers can negotiate for better prices and quality.
Bargaining power of suppliers: Moderate as raw materials for hyaluronic acid products are commodity chemicals with few suppliers controlling the market. Suppliers have advantage over prices but development of alternative sources can reduce their control.
Threat of new substitutes: Moderate threat from new substitute products. Alternative dermal fillers, supplements are available but hyaluronic acid products have established brand value and clinical efficacy.
Competitive rivalry: High competition due to large number of global and local players. Companies focus on new product launches, mergers and acquisitions for competitive advantage.
SWOT Analysis
Strengths: Large market size and widespread application areas of hyaluronic acid products drive revenue. Established brands with proven efficacy and safety attract more consumers.
Weaknesses: Higher prices of innovative products limit their accessibility. Dependence on few raw material suppliers increases input costs.
Opportunities: Expanding aging population and rising medical tourism in developing nations boost sales. New application areas in wound care and ophthalmology present growth avenues.
Threats: Stringent regulatory approvals and quality standards increase compliance costs. Higher R&D investments required to replace existing products limit entry of small players.
Key Takeaways
The global hyaluronic acid products market is expected to witness high growth over the forecast period of 2023 to 2030. The market size is projected to reach upwards of US$ 3,343.5 Mn by 2024 growing at a CAGR of 7.4% through 2030.
Regional analysis indicates North America dominates currently due to rapid adoption of new technologies. However, Asia Pacific is poised to grow at the fastest pace supported by large patient population, increasing medical expenditures and developing healthcare infrastructure in countries like China and India.
Key players operating in the hyaluronic acid products market are Anika Therapeutics, Inc.,Fidia Farmaceutici S.p.A.,Sanofi S.A,Ferring B.V.,Viatris Inc.,Croma-Pharma,Seikagaku Corporation,Zimmer Biomet Holdingd,Lifecore Biomedical LLC,LG Chem,Bioventus LLC,Smith & Nephew plc,Shanghai Jingfeng Pharmaceutical Co., Ltd.,Nestle (Galderma),Bausch Health Companies Inc. Companies Inc. (Salix Pharmaceuticals, Inc.),Allergan Plc. These companies are investing heavily in R&D to gain first-mover advantage through novel products.
